Answers are grounded in this paper and cite their sources.
BACKGROUND: Insulin efsitora alfa (efsitora) is a once-weekly basal insulin. This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin degludec (degludec) in adults with type 1 diabetes. METHODS: This randomised, 52-week, parallel-design, open-label, treat-to-target non-inferiority study conducted at 82 global health-care centres, randomly assigned (1:1) adults (ie, those aged ≥18 years) with type 1 diabetes glycated haemoglobin A FINDINGS: Between Aug 12, 2022, and May 7, 2024, of 893 participants enrolled, 692 (77%) participants were randomly assigned to once-weekly efsitora or once-daily degludec, and 623 (90%) participants completed the study. Mean HbA INTERPRETATION: In adults with type 1 diabetes, once-weekly efsitora showed non-inferior HbA FUNDING: Eli Lilly and Company.
No takes yet. Share an insight, caveat, or question.
Bergenstal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: